FY25 release: dead money in the short/mid-term
02/03/26 -"Despite the very decent valuation (5x EBITDA) and high yield (c.9% currently), our opinion turns negative after a new downward revision of our forecasts, after a sluggish FY25 and soft outlook for ..."
Pages
48
Language
English
Published on
02/03/26
You may also be interested by these reports :
05/03/26
Rentokil Initial reported H2 results in line with market expectations for sales, EBIT, and EPS. North America continues to show signs of ...
04/03/26
Bilfinger’s full-year results for 2025 exceeded expectations in ways that merit closer examination. Free cash flow surged 75% to €330 million, the ...
02/03/26
Despite the very decent valuation (5x EBITDA) and high yield (c.9% currently), our opinion turns negative after a new downward revision of our ...
27/02/26
The group reported anticipated results for FY25. Notably, management changes were announced with the appointment of a new CEO together with the ...